Investing.com - Roth/MKM initiated coverage on Microbot Medical (NASDAQ:MBOT) with a Buy rating and a price target of $5.50, representing a significant 149% upside from the current price of $2.21.

Investing.com - H.C. Wainwright has reiterated its Buy rating on Microbot Medical (NASDAQ:MBOT) with a price target of $12.00 following the company’s third-quarter 2025 financial results. This target ...

Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...

KUALA LUMPUR: Over 100,000 technologists and technicians including those specialising in emerging technologies are currently registered under the Malaysia Board of Technologists (MBOT), says Chang Lih ...

Microbot Medical ( (MBOT)) has issued an announcement. On November 5, 2025, Microbot Medical announced the limited commercial availability of its LIBERTY® Endovascular Robotic System in the U.S. This ...

Fintel reports that on October 15, 2025, HC Wainwright & Co. reiterated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 325.00% Upside As of ...

In many a school auditorium, a theater kid could be spotted sitting cross-legged with a peanut butter and jelly sandwich, surrounded by peers who had just belted their way through the entire Hamilton ...

MBOT’s main value driver is its LIBERTY robot. This is a disposable, portable endovascular robot that has great potential. LIBERTY showed strong ACCESS-PVI data and now awaits FDA 510(k) clearance for ...

Imagine this: you’re in the middle of an important project, juggling deadlines, and collaborating with a team scattered across time zones. Suddenly, your computer crashes, and hours of work vanish in ...

Microbot Medical Inc. (MBOT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...